Britain and America have forged a landmark trade agreement that will keep zero tariffs on British drug products going into the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to increase spending on medicines through the public health system. This commitment secures that import taxes on these key exports will be held at zero for a period of 36 months.
This deal follows earlier statements to dramatically increase tariffs on branded drug products, with increases floated as high as 100%.
"This arrangement with the United Kingdom reinforces the global environment for cutting-edge drugs and introduces much-needed equity to American-British medicine commerce," a statement said.
Commercial Importance
Drugs represent one of the UK's most significant exports to the US, which is by far the primary destination for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This figure accounted for a significant portion of total UK exports in that timeframe.
"This deal secures work, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key UK Commitments
The agreement involves several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at 15%. In the past, repayments were more than twenty percent.
Broader Context
This agreement comes amid a long-running tension between the drug companies and the British authorities over medicine costs and NHS adoption.
The disagreement were heightened by claims that American patients were charged several times more for the equivalent treatments than people in the other developed nations.
In recent months, several major drug company projects in the UK have been halted or scrapped, while major funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the past decade.
